
Obefazimod Shows Long-Term Benefits in Ulcerative Colitis
METHODOLOGY:
Obefazimod is an investigational oral small molecule that enhances the expression of a single micro-RNA regulating the inflammatory response. In a phase 2b, randomised placebo-controlled 8-week induction trial, obefazimod at three different doses achieved the primary endpoint in patients with moderate to severely active UC.
This 96-week open-label maintenance study was conducted including 217 patients (mean age, 42.1 years; 61.3% men) with moderate to severely active UC who were recruited at 69 study centres in 14 countries. All participants received 50 mg obefazimod once daily, regardless of their previous treatment and irrespective of their clinical response at the end of the induction trial.
After week 48, patients who showed clinical response, defined as a decrease in the modified Mayo score ≥ 2 points and ≥ 30% from baseline plus a decrease in the rectal bleeding subscore ≥ 1 or absolute rectal bleeding subscore ≤ 1, continued the treatment up to week 96.
Efficacy endpoints included rates of clinical remission, clinical response, endoscopic improvement, and endoscopic remission, along with the change in the stool frequency and faecal calprotectin levels from baseline of the maintenance study, assessed using non-responder imputation for missing data.
Safety measures comprised the incidence of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), discontinuations due to TEAEs, drug-related SAEs, and clinically significant laboratory abnormalities.
TAKEAWAY:
Of the 217 patients, 164 completed the study at week 96. By weeks 48 and 96, 81.6% and 72.8% of patients achieved a clinical response and 54.8% and 52.5% achieved clinical remission, respectively; endoscopic improvement was seen in 59.0% of patients and endoscopic remission seen in 35.9% at week 96.
Faecal calprotectin levels decreased from a median of 204.7 µg/g at baseline in the maintenance study to 89.6 µg/g at week 96, and 61.9% of patients achieved levels below 150 µg/g at week 96.
At both weeks 48 and 96, the proportion of patients who achieved the efficacy endpoints was numerically higher among those who showed a clinical response at week 8 than among those who did not. A proportion of patients also achieved corticosteroid-free endoscopic improvement and remission.
Overall, 68.2% of patients experienced at least one TEAE, with the most common being COVID-19 infection (14.3%) and headache (11.5%). TESAEs occurred in 8.3% of patients, and 7.8% discontinued because of TEAEs. No new safety signals or clinically meaningful changes in laboratory parameters were noted.
IN PRACTICE:
"[The study] findings suggest that long-term treatment with obefazimod provides continued improvement of clinical symptoms of the disease," the authors of the study wrote. "Although the central evaluation of endoscopy data reduced the risk of bias in this open-label study, the results must be interpreted with caution due to the absence of a control group," they added.
SOURCE:
This study was led by Severine Vermeire, University Hospitals Leuven, Leuven, Belgium. It was published online on May 26, 2025, in the Journal of Crohn's and Colitis .
LIMITATIONS:
Steroid cycling was not considered in the non-responder imputation method, which may have limited the interpretation of corticosteroid-free outcomes.
DISCLOSURES:
This study was supported by Abivax S.A. Seven authors reported being employees of Abivax. One author reported owning stocks in Abivax. Several authors reported receiving consultancy and/or speaking fees and grants and being consultants and advisory board members for various pharmaceutical companies.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'
Yahoo
5 days ago
- Yahoo
David Nabarro, British physician who led UN response to Ebola and COVID-19, dies
GENEVA (AP) — Dr. David Nabarro, a British physician who led the U.N. response to some of the biggest health crises in recent years, including bird flu, Ebola and the coronavirus pandemic, has died. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Nabarro's death on social media platform X. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals,' Tedros wrote Saturday. 'His work touched and impacted so many lives across the world.' King Charles knighted Nabarro in 2023 for his contributions to global health after he served as one of six special envoys to the WHO on COVID-19. He won the 2018 World Food Prize for his work on health and hunger issues. He also was a candidate for the top job at the WHO in 2017 but lost out to Tedros in the final round of voting. Nabarro left the U.N. later that year. The 4SD Foundation, a social enterprise in Switzerland focused on mentoring the next generation of leaders in global sustainable development, said its strategic director died at his home Friday in a 'sudden passing.' Other details were not immediately available. 'David's generosity and unwavering commitment to improve the lives of others will be sorely missed,' the foundation wrote on its website Saturday. Survivors include his wife, Flo, as well as his five children and seven grandchildren. Solve the daily Crossword

Associated Press
5 days ago
- Associated Press
David Nabarro, British physician who led UN response to Ebola and COVID-19, dies
GENEVA (AP) — Dr. David Nabarro, a British physician who led the U.N. response to some of the biggest health crises in recent years, including bird flu, Ebola and the coronavirus pandemic, has died. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Nabarro's death on social media platform X. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals,' Tedros wrote Saturday. 'His work touched and impacted so many lives across the world.' King Charles knighted Nabarro in 2023 for his contributions to global health after he served as one of six special envoys to the WHO on COVID-19. He won the 2018 World Food Prize for his work on health and hunger issues. He also was a candidate for the top job at the WHO in 2017 but lost out to Tedros in the final round of voting. Nabarro left the U.N. later that year. The 4SD Foundation, a social enterprise in Switzerland focused on mentoring the next generation of leaders in global sustainable development, said its strategic director died at his home Friday in a 'sudden passing.' Other details were not immediately available. 'David's generosity and unwavering commitment to improve the lives of others will be sorely missed,' the foundation wrote on its website Saturday. Survivors include his wife, Flo, as well as his five children and seven grandchildren.